Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + docetaxel
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Aflibercept + docetaxel is a combination therapy consisting of aflibercept, a recombinant human fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF), and docetaxel, a cytotoxic taxane chemotherapy agent. Aflibercept inhibits angiogenesis by binding to VEGF-A, VEGF-B, and PlGF with high affinity, preventing their interaction with native receptors on the surface of endothelial cells. Docetaxel promotes microtubule assembly while inhibiting disassembly, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells. This combination has been investigated primarily in advanced solid tumors such as metastatic castrate-resistant prostate cancer and other advanced malignancies[1][2][4][5].
02
Targets
PGF (Placental Growth Factor)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on aflibercept + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + docetaxel.